For the recognition of World TB Day on March 24, 2016, the USAID-funded Systems for Improved Access to Pharmaceuticals and Services (SIAPS) Program team launched a blog post highlighting successes and lessons learned in Swaziland. The blog recounts the history of bedaquiline entrance into the market, the potential challenges surrounding this new TB drug, and the establishment of a global bedaquiline donation program by USAID, partnered with Johnson & Johnson affiliate Janssen, to answer these challenges.
The USAID-funded SIAPS Program provides technical assistance to countries involved in the donation program, one of which being Swaziland. With a high TB/HIV co-infection rate, increasing numbers of confirmed XDR-TB patients, and some patients experiencing severe adverse reactions to existing TB medicines, Swaziland demonstrated a clear need for bedaquiline. SIAPS Program worked extensively with Swaziland to ensure the country’s health and pharmaceutical systems were prepared to accept the first shipment of donated bedaquiline, which arrived in December 2015.
Read more about USAID and SIAPS steps toward creating strong systems in Swaziland and important lessons learned during the process.